Home›Stock Screener›Crop Life Science›Financial Statements

Crop Life Science Complete Financial Statements

4 Years of Data
2026 - 2023

In FYNone, Crop Life Science (CLSL) reported revenue ₹0 Cr, net profit ₹0 Cr and EPS ₹0.00, with a net profit margin of 3.3% and ROE of 8.0%. Full financial statements from FY2023 to FY2026 (4 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Compare with CLSL stock valuation models to assess whether the stock is under or overvalued.

Complete Financial Data Export

Profitability Ratios

Net Profit Margin 3.35% 2026 data
EBITDA Margin 9.57% 2026 data
Operating Margin 9.00% 2026 data
Return on Assets 3.37% 2026 data
Return on Equity 7.95% 2026 data

Balance Sheet Ratios

Current Ratio 29.50 2026 data
Equity Ratio 42.31% 2026 data
Asset Turnover 1.00 2026 data

CLSL Revenue, Net Profit & EBITDA — Year-on-Year Growth

CLSL YoY (March 2026 vs Period) — revenue -100.0%, net profit -100.0%, EBITDA -100.0%, expenses -100.0%.

Revenue Growth
-100.0%
Year-over-Year
Net Profit Growth
-100.0%
Year-over-Year
EBITDA Growth
-100.0%
Year-over-Year
Expense Growth
-100.0%
Year-over-Year
Assets Growth
+14.3%
Year-over-Year
Equity Growth
+8.6%
Year-over-Year
Operating Cash Flow Growth
-300.0%
Year-over-Year
Investing Cash Flow Growth
+150.0%
Year-over-Year
Financing Cash Flow Growth
-28.6%
Year-over-Year

CLSL Income Statement — Revenue, EBITDA & Net Profit

Crop Life Science revenue ₹0 Cr, EBITDA ₹0 Cr, net profit ₹0 Cr, EPS ₹0.00 (None) — net profit margin 3.3%. For live price, earnings ratios and company overview, see Crop Life Science screener.

Periods ₹ Crores
Particulars None March 2026 March 2025 March 2024 March 2023
Revenue 0 209 202 201 132
Expenses 0 189 184 186 120
EBITDA 0 20 17 15 13
Operating Profit Margin % 0.00% 9.00% 8.00% 6.00% 9.00%
Depreciation 0 5 5 3 4
Interest 0 5 5 3 3
Profit Before Tax 0 9 8 8 6
Tax 0 3 2 2 2
Net Profit 0 7 6 6 4
Earnings Per Share (₹) 0.00 3.79 3.27 3.54 3.39

CLSL Balance Sheet — Assets, Liabilities & Shareholders' Equity

CLSL total assets ₹208 Cr, total equity ₹88 Cr, total liabilities ₹ Cr (2026) — ROE 8.0%.

Years Annual Data ₹ Crores
Particulars 2026 2025 2024 2023
ASSETS
Total Assets 208 182 180 102
Current Assets 177 142 140 86
Fixed Assets 30 38 39 16
Capital Work in Progress 0 0 0 0
Investments 1 1 0 0
Other Assets 177 143 141 86
LIABILITIES
Total Liabilities
Current Liabilities 6 8 11 6
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 88 81 76 41
Share Capital 17 17 17 12
Reserves & Surplus 67 60 55 29

CLSL Cash Flow Statement — Operating, Investing & Financing

Crop Life Science operating cash flow ₹-8 Cr, investing ₹2 Cr, financing ₹-9 Cr, net cash flow ₹-15 Cr (2026).

Periods ₹ Crores
Particulars March 2026 March 2025 March 2024 March 2023
Operating Activities -8 -2 -8 2
Investing Activities 2 -4 -3 -5
Financing Activities -9 -7 13 1
Net Cash Flow -15 -12 2 -2